The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status

Medicine and Dentistry

• Cancer Inhibition 20%
• Cell Cycle Arrest 20%
• Cell Cycle Checkpoint 20%
• Cell Marker 20%
• Cell Proliferation 20%
• Epidermal Growth Factor Receptor 100%
• Experimental Glioma 20%
• Ganglioglioma 100%
• Glioblastoma 100%
• Glioma Cell 40%
• Growth Factor 20%
• Growth Inhibition 20%
• In Vitro 40%
• Mitogen-Activated Protein Kinase 20%
• Neoplasm 60%
• Protein Kinase B 20%
• Receptor 20%
• Receptor Expression 20%
• Receptor Family 20%
• Stem Cell 20%
• Tumor Progression 60%
• Tumor Suppressor Protein 100%
• Xenograft 40%

Keyphrases

• AKT Pathway 8%
• Antitumor Effect 8%
• Cell Cycle Arrest 8%
• Cell Encapsulation 8%
• Constitutively Active 8%
• Diverse Patients 8%
• Downstream Effectors 8%
• Downstream Signaling 8%
• EGF Receptor 100%
• EGFRvIII 16%
• Encapsulated Cells 8%
• Encapsulation Technology 8%
• Epidermal Growth Factor Receptor 16%
• Epidermal Growth Factor Receptor Expression 8%
• Epidermal Growth Factor Receptor Family 8%
• Glioblastoma Therapy 8%
• Glioblastoma Xenografts 8%
• Growth Factor Signaling 8%
• Growth Inhibition 8%
• In Situ Delivery 8%
• In Vitro Growth 8%
• Induced Growth 8%
• Isolated Patients 8%
• Local Delivery 8%
• LRIG1 100%
• Mouse Survival 8%
• Negative Regulator 8%
• Orthotopic Glioma 8%
• Patient-derived 8%
• Proliferation in Vitro 8%
• Receptor Status 100%
• Soluble Form 100%
• Stem Cell Markers 8%
• Suppressor Cells 8%
• Survival Benefit 8%
• Tumor Growth in Vivo 8%
• Tumor Inhibition 8%
• Tumor-bearing Mice 8%
• Variable Expression 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Cancer Inhibition 20%
• Cell Marker 20%
• Epidermal Growth Factor Receptor 100%
• Experimental Glioma 20%
• Glioblastoma 100%
• Growth Factor 20%
• Mitogen Activated Protein Kinase 20%
• Neoplasm 60%
• Protein Kinase B 20%
• Receptor 20%
• Tumor Growth 60%
• Tumor Suppressor Protein 100%